Patient's Anastrozole Compliance to Therapy Programme (PACT) influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early breast cancer

Introduction: An important requirement for the effectiveness of any therapeutic intervention is optimal compliance. In the adjuvant treatment of hormone responsive breast cancer, existing data document that 23% and 50% of patients were non-compliant after the first and fourth year of tamoxifen therapy. To date, no data on compliance to aromatase inhibitors (AI) outside of RCTs has been reported.